

1     Detection and replication of epistasis influencing  
2                                     transcription in humans

3     Gibran Hemani<sup>1,2,\*</sup>, Konstantin Shakhbazov<sup>1,2</sup>, Harm-Jan Westra<sup>3</sup>,  
4     Tonu Esko<sup>4,5,6</sup>, Anjali K Henders<sup>7</sup>, Allan F McRae<sup>1,2</sup>, Jian Yang<sup>2</sup>,  
5     Greg Gibson<sup>8</sup>, Nicholas G Martin<sup>7</sup>, Andres Metspalu<sup>4</sup>, Lude  
6     Franke<sup>3</sup>, Grant W Montgomery<sup>7,+</sup>, Peter M Visscher<sup>1,2,+</sup>, and  
7                                     Joseph E Powell<sup>1,2,+</sup>

8     <sup>1</sup>University of Queensland Diamantina Institute, University of  
9     Queensland, Princess Alexandra Hospital, Brisbane, Queensland,  
10    Australia. <sup>2</sup>Queensland Brain Institute, University of Queensland,  
11    Brisbane, QLD, Australia. <sup>3</sup>Department of Genetics, University  
12    Medical Center Groningen, University of Groningen, Hanzeplein 1,  
13    Groningen, the Netherlands. <sup>4</sup>Estonian Genome Center, University  
14    of Tartu, Tartu, 51010, Estonia. <sup>5</sup>Medical and Population  
15    Genetics, Broad Institute, Cambridge, MA, 02142, US. <sup>6</sup>Divisions  
16    of Endocrinology, Children’s Hospital, Boston, MA, 02115, US.  
17    <sup>7</sup>Queensland Institute of Medical Research, Brisbane, Queensland,  
18    Australia. <sup>8</sup>School of Biology and Centre for Integrative Genomics,  
19    Georgia Institute of Technology, Atlanta, Georgia United States of  
20    America. <sup>+</sup>These authors contributed equally. <sup>\*</sup>Corresponding  
21                                     author: g.hemani@uq.edu.au

## Abstract

Epistasis is the phenomenon whereby one polymorphism's effect on a trait depends on other polymorphisms present in the genome. The extent to which epistasis influences complex traits<sup>1</sup> and contributes to their variation<sup>2,3</sup> is a fundamental question in evolution and human genetics. Though epistasis has been demonstrated in artificial gene manipulation studies in model organisms,<sup>4,5</sup> and examples have been reported in other species,<sup>6</sup> few convincing examples with independent replication exist for epistasis amongst natural polymorphisms in human traits.<sup>7,8</sup> Its absence from empirical findings may simply be due to its low incidence in the genetic control of complex traits,<sup>2,3</sup> but an alternative view is that it has previously been too technically challenging to detect due to statistical power and computational issues.<sup>9</sup> Here we show that, using advanced computation techniques<sup>10</sup> and a gene expression study design, many instances of epistasis are found between common single nucleotide polymorphisms (SNPs). In a cohort of 846 individuals with data on 7339 gene expression levels in peripheral blood, we found 501 significant pairwise epistatic interactions between common SNPs acting on the expression levels of 238 genes ( $p < 2.91 \times 10^{-16}$ ). Replication of these interactions in two independent data sets<sup>11,12</sup> showed both concordance of direction of epistatic effects ( $p = 5.56 \times 10^{-31}$ ) and enrichment of interaction  $p$ -values, with 30 being significant at a conservative threshold of  $p < 0.05/501$ . There was evidence of functional enrichment for the interacting SNPs, for instance 44 of the genetic interactions are located within 5Mb of regions of known physical chromosome interactions<sup>13</sup> ( $p = 1.8 \times 10^{-10}$ ). Epistatic networks of three SNPs or more influence the expression levels of 129 genes, whereby one *cis*-acting SNP is modulated by several *trans*-acting SNPs. For example MBNL1 is influenced by an additive effect at rs13069559 which itself is masked by *trans*-SNPs on 14 different chromosomes, with nearly identical genotype-phenotype (GP) maps for each *cis-trans* interaction. This study presents the first evidence for multiple instances of segregating common polymorphisms interacting to influence human traits.

## Main text

In the genetic analysis of complex traits it is usual for SNP effects to be estimated using an additive model where they are assumed to contribute independently and cumulatively to the mean of a trait. This framework has been successful in identifying thousands of associations.<sup>14</sup> But to date, though its contribution to phenotypic variance is frequently the subject of debate,<sup>1-3</sup> there is little empirical exploration of the role that epistasis plays in the architecture of complex traits in humans.<sup>7,8</sup> Beyond the prism of human association studies there is evidence for epistasis, not only at the molecular scale from artificially induced mutations<sup>4</sup> but also at the evolutionary scale in fitness adaptation<sup>15</sup> and speciation.<sup>16</sup>

Methods are now available to overcome the computational problems involved in searching for epistasis, but its detection still remains problematic due to re-

duced statistical power. For example increased dependence on linkage disequilibrium (LD) between causal SNPs and observed SNPs,<sup>17,18</sup> increased model complexity in fitting interaction terms,<sup>19</sup> and more extreme significance thresholds to account for increased multiple testing<sup>9</sup> all make it more difficult to detect epistasis in comparison to additive effects. Thus, when combined with small genetic effect sizes, as is expected in most complex traits of interest,<sup>14</sup> the power to detect epistasis diminishes rapidly. There are two simple ways to overcome this problem. One is by using extremely large sample sizes;<sup>20</sup> another is by analysing traits that are likely to have large effect sizes among common variants. Because our focus was to ascertain the extent to which instances of epistasis arises from natural genetic variation we designed a study around the latter approach and searched for epistatic genetic effects that influence gene expression levels. Transcription levels can be measured for thousands of genes and like most complex diseases, these expression traits are typically heritable.<sup>21</sup> But unlike complex diseases, genetic associations with gene expression commonly have very large effect sizes that explain large proportions of the genetic variance,<sup>22</sup> making them good candidates to search for epistasis, should it exist.

In our discovery dataset (Brisbane Systems Genetics Study, BSGS<sup>23</sup>) of 846 individuals genotyped at 528,509 SNPs, we used a two stage approach to identify genetic interactions. First, we exhaustively test every pair of SNPs for pairwise effects against each of 7339 expression traits in peripheral blood (family-wise error rate of 5% corresponding to a significance threshold of  $p < 2.91 \times 10^{-16}$ , Methods). Second, we filtered the SNP pairs from stage 1 on LD and genotype class counts, and tested the remaining pairwise effects for significant interaction terms and used a Bonferroni correction for multiple testing (estimated type 1 error rate  $0.05 \leq \alpha \leq 0.14$ , Methods, Supplementary Figure S1). Using this design we identified 501 putative genetic interactions influencing the expression levels of 238 genes (Supplementary Table S1). Of the 501 discovery interactions, 434 had available data and passed filtering (Methods) in two independent replication datasets, Fehrmann<sup>12</sup> and the Estonian Genomics Centre University of Tartu (EGCUT),<sup>11</sup> in which we saw convincing evidence for replication. We used the summary statistics from the replication datasets to perform a meta analysis to obtain an independent  $p$ -value for the putative interactions, and 30 were significant after applying a Bonferroni correction for multiple testing (5% significance threshold  $p < 0.05/501$ , Table 1). To quantify the similarity of GP maps between the independent datasets (Figure 1) we decomposed the genetic effects of each of the SNP pairs into orthogonal additive, dominance and epistatic effects ( $A1$ ,  $A2$ ,  $D1$ ,  $D2$ ,  $A \times A$ ,  $A \times D$ ,  $D \times A$ ,  $D \times D$ ) and tested for concordance of the sign of the most significant effect (Supplementary Table S3, Methods). Sign concordance between the discovery and both replication datasets was observed in 22 out of the 30 significantly replicated interactions (expected value = 7.5 under the null hypothesis of no interactions,  $p = 3.76 \times 10^{-8}$ ).

In addition, using the meta analysis from the replication samples only, we observed that 316 of the remaining 404 discovery SNP pairs had replication interaction  $p$ -values more extreme than the 2.5% confidence interval of the quantile-quantile plot against the null hypothesis of no interactions where  $p$ -

values are assumed to be uniformly distributed ( $p \ll 1.0 \times 10^{-16}$ , Figure 2 and Supplementary Figure S2). Concordance of the direction of the effect of the largest variance component was also highly significant ( $p = 5.71 \times 10^{-31}$ , Supplementary Table S3). The congruence of the epistatic networks in discovery and replication datasets is shown in Figure 3, demonstrating that these complex genetic patterns are common even across independent datasets. A further replication was attempted using the Centre for Health Discovery and Wellbeing (CHDWB) dataset,<sup>24</sup> but only 20 of the SNP pairs passed filtering because the sample size was small ( $n = 139$ ), and likely due to insufficient power we found no evidence for replication (Supplementary Figure S6).

It should be noted that although it is a necessary step to establish the veracity of the interactions from the discovery set, replication of epistasis is difficult in practice. For example, LD between causal variants and observed markers plays an important role. Not only is the dependence on LD much greater for epistatic effects than for additive effects (Supplementary Figure S7), but when estimating epistatic variance it is more sensitive to changes in LD between observed SNPs and causal variants between independent samples when compared to additive effects (Supplementary Figure S8), and this has a direct effect on statistical power for replication. The sampling variance of LD  $r$  leads to the ascertainment of marker associations with higher sample  $r$  in the discovery stage in comparison to the replication stage. However, the average decrease in  $\hat{r}^x$  in replication samples becomes larger as  $x$  increases (Methods, Supplementary Figure S9). For example, the decrease in  $\hat{r}^8$  (which is proportional to the power of detecting  $D \times D$  effects), is on average three fold greater than the decrease in  $\hat{r}^2$  (which is proportional to the power of detecting additive effects).

Though seldom the focus of association studies, SNPs with known main effects are often tested for additive  $\times$  additive genetic interactions,<sup>9</sup> but our analysis shows that this is unlikely to be the most effective strategy for its detection. The majority of our discovery interactions comprised of one SNP that was significantly associated with the gene expression level in the discovery dataset, and one SNP that had no previous association<sup>22</sup> (439 out of 501, Methods). Only nine interactions were between SNPs that both had known main effects while 64 were between SNPs that had no known main effects. Additionally, we observed that the largest epistatic variance component for the 501 interactions was equally divided amongst additive  $\times$  additive, additive  $\times$  dominance, dominance  $\times$  additive and dominance  $\times$  dominance at the discovery stage ( $p = 0.22$  for departure from expectation). This is not surprising because the patterns of epistasis used for statistical decomposition (*i.e.*  $A \times A$ ,  $A \times D$ ,  $D \times A$ ,  $D \times D$ ) are simply convenient orthogonal parameterisations of a two locus model, and are not intended to model biological function.<sup>25</sup>

Of the discovery interactions, 47 were *cis-cis* acting (both SNPs were on the same chromosome as the expression gene, median distance between interacting SNPs is 1.83Mb), 441 were *cis-trans*-acting, and 13 were *trans-trans*-acting. We observed a wide range of significant GP maps (Figure 1) but the most common pattern of epistasis that we detected involved a *trans*-SNP masking the effect of an additive *cis*-SNP. For example, MBNL1 (involved in RNA modification and

regulation of splicing<sup>26</sup>) has a *cis* effect at rs13069559 which in turn is controlled by 13 *trans*-SNPs and one *cis*-SNP that each exhibit a masking pattern, such that when the *trans*-SNP is homozygous for the masking allele the decreasing allele of the *cis*-SNP no longer has an effect (Supplementary Figure S10). Each of these interactions has evidence for replication in at least one dataset and six are significantly replicated at the Bonferroni level (Supplementary Figure S3). We see similar epistatic networks involving multiple (eight or more) *trans*-acting SNPs for other gene expression levels too, for example TMEM149 (Supplementary Figure S11), NAPRT1 (Supplementary Figure S12), TRAPPC5 (Supplementary Figure S13), and CAST (Supplementary Figure S14). We observed that from pedigree analysis these five gene expression phenotypes had non-additive variance component estimates within the 95th percentile of the 17,994 gene expression phenotypes that were analysed previously<sup>22</sup> (Supplementary Table S2, Methods).

In total the 501 interactions comprised 781 unique SNPs, which we analysed for functional enrichment (Methods). We tested the SNPs for cell-type specific overlap with transcriptionally active chromatin regions, tagged by histone-3-lysine-4,tri-methylation (H3K4me3) chromatin marks, in 34 cell types<sup>27</sup> (Supplementary Figure S5). There was significant enrichment for *cis*-acting SNPs in haematopoietic cell types only ( $p < 1 \times 10^{-4}$  for the three tissues with the strongest enrichment after adjusting for multiple testing). However *trans*-acting SNPs did not show any tissue specific enrichment ( $p > 0.1$  for all tissues). This difference between *cis* and *trans* SNPs suggests different roles in epistatic interactions where tissue specificity is provided by the *cis* SNPs. There is also enrichment for *cis*-SNPs to be localised in regions with regulatory genomic features as measured by chromatin states<sup>28</sup> (Supplementary Figure S4).

We also demonstrate physical organisation of interacting loci within the cell, suggesting a mechanism by which biological function can lead to epistatic genetic variance. It has been shown that different chromosomal regions spatially colocalise in the cell through chromatin interactions.<sup>13</sup> We cross-referenced our epistatic SNPs with a map of chromosome interacting regions ( $n = 96,139$ ) in K562 blood cell lines<sup>29</sup> (Methods) and found that 44 epistatic interactions mapped to within 5Mb ( $p < 1.8 \times 10^{-10}$ ), (Supplementary Figure S15). Interaction of distant loci may occur through physical proximity in transcriptional factories that organise across different chromosome regions and can regulate transcription of related genes.<sup>30,31</sup>

Though we present many instances of epistasis, quantifying its relative importance to complex traits in humans remains an open question. In this study we are able to identify 238 gene expression traits with at least one significant interaction given our experiment-wide threshold, where the minimum estimated variance explained by the epistatic effects of any interaction was 2.1% of phenotypic variance. Taking results from our previously published eQTL<sup>23</sup> we calculated that 1848 of the 7339 gene expression levels analysed were influenced by additive effects where the estimated additive variance of a locus was 2.1% or greater. Thus, we can infer that the number of instances of large additive effects is significantly greater than the number of instances of large epistatic effects.

205 In terms of their contribution to complex traits a more important metric  
 206 might be the proportion of the variance that the epistatic loci explain.<sup>2</sup> Ide-  
 207 ally one would approach this question from a whole genome perspective<sup>32</sup> but  
 208 this is intractable for non-additive variance components. Nevertheless, some  
 209 inference can be made from the ascertained effects in these analyses and it is  
 210 evident that estimated additive variance is overall a larger component than esti-  
 211 mated epistatic variance, as has been argued previously.<sup>2,3</sup> Taking all additive  
 212 effects detected in Powell *et al* (2012) that have additive variance explaining  
 213 2.1% or greater of phenotypic variance, we calculated that the proportion of to-  
 214 tal phenotypic variance of all 7339 gene expression levels explained by additive  
 215 effects alone was 2.16%. By contrast, the estimated epistatic variance from the  
 216 interacting SNPs detected in this study on average explain a total of 0.22% of  
 217 phenotypic variance, approximately ten times lower than the estimated additive  
 218 variance. There are several caveats to this comparison. Firstly, the ratio of ad-  
 219 ditive to epistatic variance may differ at different minimum variance thresholds,  
 220 and our estimate is determined by the threshold used. Secondly, the power of a  
 221 1 *d.f.* test exceeds that of an 8 *d.f.* test. Thirdly, the non-additive variance at  
 222 causal variants is expected to be underestimated by observed SNPs in compar-  
 223 ison to estimates for additive variance. This is due to differences in the rate of  
 224 decay of the estimate of the genetic variance of the causal SNPs as LD decreases  
 225 with the observed SNPs. And forthly, the extent of winner’s curse in estimation  
 226 of effect sizes may differ between the the two studies.

227 Overall, we have demonstrated that it is possible to identify and replicate  
 228 epistasis in complex traits amongst common human variants, despite the rela-  
 229 tive contribution of pairwise epistasis to phenotypic variation being small. The  
 230 bioinformatic analysis of the significant epistatic loci suggests that there are a  
 231 large number of possible mechanisms that can lead to non-additive genetic varia-  
 232 tion. Further research into such epistatic effects may provide a useful framework  
 233 to understanding molecular mechanisms and complex trait variation in greater  
 234 detail. With computational techniques and data now widely available the search  
 235 for epistasis in larger datasets for traits of broader interest is warranted.

## 236 Methods Summary

237 We searched for pairwise epistasis exhaustively in the BSGS discovery dataset,<sup>23</sup>  
 238 which comprises 846 individuals who are genotyped at 528,509 autosomal SNPs.  
 239 Each individual had gene expression levels measured in peripheral blood at  
 240 47,323 probes. Only the probes that passed quality control and had significant  
 241 expression in  $\geq 90\%$  of individuals were used in the analysis (7,339 probes  
 242 representing 6,158 RefSeq genes). Recent hardware and software<sup>10</sup> advances  
 243 that use graphics processing units (GPUs) made it possible to perform the  
 244  $1.03 \times 10^{15}$  statistical tests to complete this analysis. We used permutation  
 245 analysis<sup>33</sup> to calculate an experiment-wide significance threshold of  $T_e = 2.91 \times$   
 246  $10^{-16}$  at the 5% family-wise error rate (FWER). SNP pairs were modelled for  
 247 full genetic effects, including marginal additive and dominance at both SNPs  
 248 plus four interaction terms. Though we could have used a less complex model to

improve statistical efficiency, we deemed it important to be agnostic about the type of epistasis that might exist, and therefore chose not to over-parameterise the test.<sup>18,19</sup> Because there are many large marginal effects present in these data it was necessary to perform several filtering steps to exclude SNP pairs that were significant due to marginal effects alone. All SNP pairs with LD  $r^2 > 0.1$  and  $D'^2 > 0.1$  were removed to minimise the possibility of haplotype effects. All SNP pairs were required to have at least five data points in all nine genotype classes. If multiple SNP pairs were present on the same chromosomes for a particular expression trait then only the sentinel SNP pair was retained. Finally, a nested test contrasting the full genetic model against the marginal additive and dominance model was performed for each remaining SNP pair (Methods), resulting in 501 significant interactions after Bonferroni correction for multiple testing of the filtered SNPs. The 501 significant SNP pairs were carried forward for replication in two independent datasets that used the same expression assays for analysing transcription in peripheral blood, the Fehrmann dataset<sup>12</sup> ( $n = 1240$ ) and the Estonian Genome Centre University of the University of Tartu (EGCUT) dataset<sup>11</sup> ( $n = 891$ ). Of these, 434 passed filtering in both replication datasets. A meta analysis on the interaction  $p$ -values from each replication dataset was performed to provide an overall replication statistic for each putative interaction.

## Acknowledgements

We are grateful to the volunteers for their generous participation in these studies. We thank Bill Hill, Chris Haley and Lars Ronnegard for helpful discussions and comments.

This work could not have been completed without access to high performance GPGPU compute clusters. We acknowledge iVEC for the use of advanced computing resources located at iVEC@UWA ([www.ivec.org](http://www.ivec.org)), and the Multi-modal Australian ScienceS Imaging and Visualisation Environment (MASSIVE) ([www.massive.org.au](http://www.massive.org.au)). We also thank Jake Carroll and Irek Porebski from the Queensland Brain Institute Information Technology Group for HPC support.

The University of Queensland group is supported by the Australian National Health and Medical Research Council (NHMRC) grants 389892, 496667, 613601, 1010374 and 1046880, the Australian Research Council (ARC) grant (DE130100691), and by National Institutes of Health (NIH) grants GM057091 and GM099568.

The QIMR researchers acknowledge funding from the Australian National Health and Medical Research Council (grants 241944, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 496688 and 552485), the and the National Institutes of Health (grants AA07535, AA10248, AA014041, AA13320, AA13321, AA13326 and DA12854). We thank Anthony Caracella and Lisa Bowdler for technical assistance with the micro-array hybridisations.

The CHDWB study funding support from the Georgia Institute of Technology Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript

293 The Fehrmann study was supported by grants from the Celiac Disease  
294 Consortium (an innovative cluster approved by the Netherlands Genomics Ini-  
295 tiative and partly funded by the Dutch Government (grant BSIK03009), the  
296 Netherlands Organization for Scientific Research (NWO-VICI grant 918.66.620,  
297 NWO-VENI grant 916.10.135 to L.F.), the Dutch Digestive Disease Foundation  
298 (MLDS WO11-30), and a Horizon Breakthrough grant from the Netherlands  
299 Genomics Initiative (grant 92519031 to L.F.). This project was supported by  
300 the Prinses Beatrix Fonds, VSB fonds, H. Kersten and M. Kersten (Kersten  
301 Foundation), The Netherlands ALS Foundation, and J.R. van Dijk and the  
302 Adessium Foundation. The research leading to these results has received fund-  
303 ing from the European Communitys Health Seventh Framework Programme  
304 (FP7/2007-2013) under grant agreement 259867.

305 The EGCUT study received targeted financing from Estonian Government  
306 SF0180142s08, Center of Excellence in Genomics (EXCEGEN) and University  
307 of Tartu (SP1GVARENG). We acknowledge EGCUT technical personnel, espe-  
308 cially Mr V. Soo and S. Smit. Data analyzes were carried out in part in the  
309 High Performance Computing Center of University of Tartu.



## Tables

Table 1: Epistatic interactions significant at the Bonferroni level in two replication sets


	Gene (chr.)	SNP 1 (chr.)	SNP 2 (chr.)	BSGS <sup>2</sup>	Fehrmann <sup>3</sup>	EGCUT <sup>3</sup>	Meta <sup>4</sup>
1	ADK (10)	rs2395095 (10)	rs10824092 (10)	6.69 <sup>1</sup>	18.33 <sup>1</sup>	21.21 <sup>1</sup>	39.82 <sup>1</sup>
2	ATP13A1 (19)	rs4284750 (19)	rs873870 (19)	5.30	12.18	3.25	14.23
3	C21ORF57 (21)	rs9978658 (21)	rs11701361 (21)	9.42	6.08	16.36	21.67
4	CSTB (21)	rs9979356 (21)	rs3761385 (21)	11.99	25.20	16.72	42.27
5	CTSC (11)	rs7930237 (11)	rs556895 (11)	7.16	18.76	15.06	33.53
6	FN3KRP (17)	rs898095 (17)	rs9892064 (17)	16.16	28.24	29.39	59.95
7	GAA (17)	rs11150847 (17)	rs12602462 (17)	13.91	19.98	12.99	32.60
8	HNRPH1 (5)	rs6894268 (5)	rs4700810 (5)	15.38	8.55	3.01	10.37
9	LAX1 (1)	rs1891432 (1)	rs10900520 (1)	19.16	18.60	11.22	29.24
10	MBNL1 (3)	rs16864367 (3)	rs13079208 (3)	13.49	16.25	24.74	41.56
11	MBNL1 (3)	rs7710738 (5)	rs13069559 (3)	7.92	2.55	7.89	9.28
12	MBNL1 (3)	rs2030926 (6)	rs13069559 (3)	7.10	0.91	5.80	5.53
13	MBNL1 (3)	rs2614467 (14)	rs13069559 (3)	5.74	4.13	2.22	5.30
14	MBNL1 (3)	rs218671 (17)	rs13069559 (3)	7.63	0.62	5.82	5.23
15	MBNL1 (3)	rs11981513 (7)	rs13069559 (3)	7.71	0.43	5.36	4.58
16	MBP (18)	rs8092433 (18)	rs4890876 (18)	5.40	7.06	21.91	28.73
17	NAPRT1 (8)	rs2123758 (8)	rs3889129 (8)	8.45	15.12	16.08	30.77
18	NCL (2)	rs7563453 (2)	rs4973397 (2)	7.31	7.51	6.33	12.70
19	PRMT2 (21)	rs2839372 (21)	rs11701058 (21)	4.81	0.69	4.47	4.06
20	RPL13 (16)	rs352935 (16)	rs2965817 (16)	4.98	3.79	14.41	17.24
21	SNORD14A (11)	rs2634462 (11)	rs6486334 (11)	7.31	13.11	10.96	23.22
22	TMEM149 (19)	rs807491 (19)	rs7254601 (19)	12.16	81.55	45.78	145.78
23	TMEM149 (19)	rs8106959 (19)	rs6926382 (6)	5.80	3.06	8.80	10.72
24	TMEM149 (19)	rs8106959 (19)	rs914940 (1)	6.22	3.36	6.96	9.20
25	TMEM149 (19)	rs8106959 (19)	rs2351458 (4)	7.30	0.04	9.61	8.00
26	TMEM149 (19)	rs8106959 (19)	rs6718480 (2)	8.55	3.31	5.15	7.36
27	TMEM149 (19)	rs8106959 (19)	rs1843357 (8)	6.21	3.72	3.33	6.00
28	TMEM149 (19)	rs8106959 (19)	rs9509428 (13)	9.44	0.10	5.75	4.47
29	TRA2A (7)	rs7776572 (7)	rs11770192 (7)	8.23	3.19	1.89	4.09
30	VASP (19)	rs1264226 (19)	rs2276470 (19)	5.09	0.94	5.14	4.95

<sup>1</sup>  $-\log_{10} p$ -values for 4 *d.f.* interaction tests

<sup>2</sup> Discovery dataset

<sup>3</sup> Independent replication dataset

<sup>4</sup> Meta analysis of interaction terms between replication datasets only



**Figure 1: Replication of GP maps in two independent populations**  
The GP maps for each epistatic interaction that is significant at the Bonferroni level in both replication datasets are shown. Each GP map consists of nine tiles where each tile represents the expression level for that two-locus genotype class. Phenotypes are for gene transcript levels (dark coloured tiles = high expression, light coloured tiles = low expression). Columns of GP maps are for each independent dataset. Rows of GP maps are for each of 30 significantly replicated interactions at the Bonferroni level, corresponding to the rows in Table 1. There is a clear trend of the GP maps replicating across all three datasets.




Figure 2: **Q-Q plots of interaction  $p$ -values from replication datasets** The top panel shows all 434 discovery SNPs that were tested for interactions. Observed  $p$ -values ( $y$ -axis,  $-\log_{10}$  scale) are plotted against the expected  $p$ -values ( $x$ -axis,  $-\log_{10}$  scale). The multiple testing correction threshold for significance following Bonferroni correction is denoted by a dotted line. The bottom panel shows the same data as the top panel but excluding the 30 interactions that were significant at the Bonferroni level in the replication datasets. The shaded grey area represents the 5% confidence interval for the expected distribution of  $p$ -values. Dark blue points represent  $p$ -values that exceed the confidence interval, light blue are within the confidence interval.




Figure 3: **Discovery and replication of epistatic networks** All 434 putative genetic interactions (edges) with data common to discovery and replication sets is shown, where black nodes represent SNPs and red nodes represent traits (gene expression probes). Three hundred and forty-five interactions had  $p$ -values exceeding the 2.5% confidence interval following meta analysis of the replication data. The remaining 89 interactions that did not replicate are depicted in grey. It is evident that a large proportion of the complex networks identified in the discovery set also exist in independent populations.

## References

- <sup>1</sup> Carlborg, O. & Haley, C. S. Epistasis: too often neglected in complex trait studies? *Nature Reviews Genetics* **5**, 618–25 (2004).
- <sup>2</sup> Hill, W. G., Goddard, M. E. & Visscher, P. M. Data and Theory Point to Mainly Additive Genetic Variance for Complex Traits. *PLoS Genetics* **4** (2008).
- <sup>3</sup> Crow, J. F. On epistasis: why it is unimportant in polygenic directional selection. *Philosophical transactions of the Royal Society of London. Series B, Biological sciences* **365**, 1241–4 (2010).
- <sup>4</sup> Costanzo, M. *et al.* The genetic landscape of a cell. *Science (New York, N.Y.)* **327**, 425–31 (2010).
- <sup>5</sup> Bloom, J. S., Ehrenreich, I. M., Loo, W. T., Lite, T.-L. V. o. & Kruglyak, L. Finding the sources of missing heritability in a yeast cross. *Nature* **1–6** (2013).
- <sup>6</sup> Carlborg, O., Jacobsson, L., Ahgren, P., Siegel, P. & Andersson, L. Epistasis and the release of genetic variation during long-term selection. *Nature Genetics* **38**, 418–420 (2006).
- <sup>7</sup> Strange, A. *et al.* A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. *Nature Genetics* **42**, 985–90 (2010).
- <sup>8</sup> Evans, D. M. *et al.* Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. *Nature Genetics* **43** (2011).
- <sup>9</sup> Cordell, H. J. Detecting gene-gene interactions that underlie human diseases. *Nature Reviews Genetics* **10**, 392–404 (2009).
- <sup>10</sup> Hemani, G., Theocharidis, A., Wei, W. & Haley, C. EpiGPU: exhaustive pairwise epistasis scans parallelized on consumer level graphics cards. *Bioinformatics (Oxford, England)* **27**, 1462–5 (2011).
- <sup>11</sup> Metspalu, A. The Estonian Genome Project. *Drug Development Research* **62**, 97–101 (2004).
- <sup>12</sup> Fehrmann, R. S. N. *et al.* Trans-eQTLs reveal that independent genetic variants associated with a complex phenotype converge on intermediate genes, with a major role for the HLA. *PLoS genetics* **7**, e1002197 (2011).
- <sup>13</sup> Lieberman-Aiden, E. *et al.* Comprehensive mapping of long-range interactions reveals folding principles of the human genome. *Science (New York, N.Y.)* **326**, 289–93 (2009).

- 348 <sup>14</sup> Visscher, P. M., Brown, M. a., McCarthy, M. I. & Yang, J. Five years of  
349 GWAS discovery. *American journal of human genetics* **90**, 7–24 (2012).
- 350 <sup>15</sup> Weinreich, D. M., Delaney, N. F., Depristo, M. a. & Hartl, D. L. Darwinian  
351 evolution can follow only very few mutational paths to fitter proteins. *Science*  
352 (*New York, N.Y.*) **312**, 111–4 (2006).
- 353 <sup>16</sup> Breen, M. S., Kemena, C., Vlasov, P. K., Notredame, C. & Kondrashov, F. a.  
354 Epistasis as the primary factor in molecular evolution. *Nature* **490**, 535–538  
355 (2012).
- 356 <sup>17</sup> Weir, B. S. Linkage disequilibrium and association mapping. *Annual review*  
357 *of genomics and human genetics* **9**, 129–42 (2008).
- 358 <sup>18</sup> Hemani, G., Knott, S. & Haley, C. An Evolutionary Perspective on Epistasis  
359 and the Missing Heritability. *PLoS Genetics* **9**, e1003295 (2013).
- 360 <sup>19</sup> Marchini, J., Donnelly, P. & Cardon, L. R. Genome-wide strategies for de-  
361 tecting multiple loci that influence complex diseases. *Nature Genetics* **37**,  
362 413–417 (2005).
- 363 <sup>20</sup> Lango Allen, H. *et al.* Hundreds of variants clustered in genomic loci and  
364 biological pathways affect human height. *Nature* **467**, 832–8 (2010).
- 365 <sup>21</sup> Schadt, E. *et al.* Genetics of gene expression surveyed in maize, mouse and  
366 man. *Nature* **422**, 297–302 (2003).
- 367 <sup>22</sup> Powell, J. E. *et al.* Congruence of Additive and Non-Additive Effects on  
368 Gene Expression Estimated from Pedigree and SNP Data. *PLoS Genetics* **9**,  
369 e1003502 (2013).
- 370 <sup>23</sup> Powell, J. E. *et al.* The Brisbane Systems Genetics Study: genetical genomics  
371 meets complex trait genetics. *PloS one* **7**, e35430 (2012).
- 372 <sup>24</sup> Preinerger, M. *et al.* Blood-informative transcripts define nine common axes  
373 of peripheral blood gene expression. *PLoS genetics* **9**, e1003362 (2013).
- 374 <sup>25</sup> Cockerham, C. C. An extension of the concept of partitioning hereditary  
375 variance for analysis of covariances among relatives when epistasis is present.  
376 *Genetics* **39**, 859–882 (1954).
- 377 <sup>26</sup> Ho, T. H. *et al.* Muscleblind proteins regulate alternative splicing. *The EMBO*  
378 *journal* **23**, 3103–12 (2004).
- 379 <sup>27</sup> Trynka, G. *et al.* Chromatin marks identify critical cell types for fine mapping  
380 complex trait variants. *Nature genetics* **45**, 124–30 (2013).
- 381 <sup>28</sup> Hoffman, M., Buske, O., Wang, J. & Weng, Z. Unsupervised pattern dis-  
382 covery in human chromatin structure through genomic segmentation. *Nature*  
383 *Methods* **9**, 473–476 (2012).

- 384 <sup>29</sup> Lan, X. *et al.* Integration of Hi-C and ChIP-seq data reveals distinct types  
385 of chromatin linkages. *Nucleic acids research* **40**, 7690–704 (2012).
- 386 <sup>30</sup> Osborne, C. S. *et al.* Active genes dynamically colocalize to shared sites of  
387 ongoing transcription. *Nature genetics* **36**, 1065–71 (2004).
- 388 <sup>31</sup> Rieder, D., Trajanoski, Z. & McNally, J. G. Transcription factories. *Frontiers*  
389 *in genetics* **3**, 221 (2012).
- 390 <sup>32</sup> Visscher, P. M., Hill, W. G. & Wray, N. R. Heritability in the genomics era—  
391 concepts and misconceptions. *Nature Reviews Genetics* **9**, 255–66 (2008).
- 392 <sup>33</sup> Churchill, G. A. & Doerge, R. W. Empirical threshold values for quantitative  
393 trait mapping. *Genetics* **138**, 963–71 (1994).




Figure S1: **Type 1 error rate of two stage design assuming a null model of one large additive effect and no epistasis** In stage 1 SNPs are tested for full genetic effects (8 d.f.) and those that surpass a threshold for multiple testing are then tested for significant interaction terms in stage 2. These interaction  $p$ -values are then adjusted (Bonferroni) for the total number of tests that passed stage 1. The type 1 error rate of this two stage design is dependent on the power, which is not known empirically.






Figure S2: **Q-Q plots of interaction  $p$ -values from replication datasets, excluding the 30 points significant at the Bonferroni level** The right panel (Null) shows the interaction  $p$ -values from a meta analysis across two independent datasets on 434 randomly drawn SNP pairs. The left panel (Empirical) shows the interaction  $p$ -values from the 404 putative interactions that were not significant at the Bonferroni correction threshold. Dark blue points represent  $p$ -values that surpass the 2.5% FDR level, as in Figure 2.






Figure S3: **Gene expression traits with four or more genetic interactions** Circle plots represent the genomic positions for SNPs (linking lines) and expression probes (red points). Chromosomes are represented by black blocks and ordered from 1 to 22 clockwise, starting from the top. Grey lines represent no evidence for replication, blue lines denote interactions that are outside the 97.5% confidence interval or the Q-Q plot (Figure 2), and red lines denote replication at the Bonferroni correction level. Most interactions are characterised as being *cis-trans* to the expression probe.



**Figure S4: Location of SNPs relative to genomic features** We used chromatin segmentation<sup>28</sup> as a method for labelling genomic features. All SNPs within 1Mb and  $r^2 > 0.8$  of each *cis*- and *trans*-SNP were taken to find which genomic features ( $x$ -axis) were covered by the SNPs that compose the 501 significant interactions. Green bars represent the proportion ( $y$ -axis) of the 528,509 SNPs used in the analysis that fall within the range of the different genomic features. There is enrichment for *cis*-acting SNPs (red bars) in promotor regions, but *trans*-acting SNPs (blue bars) are not enriched for genomic features. The labels on the  $x$ -axis are as follows: E = Predicted enhancer, CTCF = CTCF enriched element, WE = Predicted weak enhancer or open chromatin cis regulatory element, PF = Predicted promoter flanking region, TSS = Predicted promoter region including transcriptional start site, T = Predicted transcribed region, R = Predicted Repressed or Low Activity region



**Figure S5: Tissue specific enrichment of SNPs in transcriptionally active regions** The locations of transcriptional activity can be predicted by chromatin marks, assayed by H3K4me3.<sup>27</sup> Enrichment *p*-values are calculated using permutation analysis for 34 different cell types (*y*-axis) in four tissue types (Rows of boxes). The dotted red line denotes significance (Bonferroni correction for 34 cell types, *x*-axis). There is enrichment for *cis*-acting SNPs in Haematopoietic tissue types only. *Trans*-acting SNPs have no tissue specificity.




Figure S6: **Q-Q plot of interaction  $p$ -values in the CDHWB dataset**  
 Twenty of the 501 discovery SNP pairs passed filtering in the CDHWB dataset (mainly due to small sample size). There is no evidence for enrichment of interaction terms, most likely due to insufficient power given the limited sample size.





Figure S7: **Sampling mean for different power terms of population  $r$  values** Power of detection and replication of epistatic interactions depends not on  $r^2$  between causal variants and observed SNPs, but on  $r^4, r^6, r^8$ . For a given population value of LD  $r$  (columns of plots), plotted is the sample mean ( $y$ -axis) of  $\hat{r}$ ,  $\hat{r}^2$  (additive),  $\hat{r}^4$  (dominance,  $A \times A$ ),  $\hat{r}^6$  ( $A \times D$ ),  $\hat{r}^8$  ( $D \times D$ ) ( $x$ -axis) for different sample sizes (coloured lines). As true  $r$  reduces the statistical power to detect epistatic variants drops dramatically under the assumption that statistical power is proportional to higher moments of  $r$ .



**Figure S8: Sampling standard deviation for different power terms of population  $r$  values** Power of detection and replication of epistatic interactions depends not on  $r^2$  between causal variants and observed SNPs, but on  $r^4, r^6, r^8$ . For a given a population value of LD  $r$  (columns of plots), plotted is the sampling standard deviation ( $y$ -axis) of  $\hat{r}$ ,  $\hat{r}^2$  (additive),  $\hat{r}^4$  (dominance,  $A \times A$ ),  $\hat{r}^6$  ( $A \times D$ ),  $\hat{r}^8$  ( $D \times D$ ) ( $x$ -axis) for different sample sizes (coloured lines). As the power term of  $r$  increases the sampling variance also increases. Supposing that there is sufficiently high  $r^x$  in the discovery sample for detection of epistasis, the replication sample is less likely to have similarly high  $r^x$  as  $x$  increases, leading to an expectation of reduced replication rates.




Figure S9: **Reduction in LD as estimated in replication data after ascertaining for high LD in discovery data** 100,000 “unobserved” causal variants (CVs) were tested for LD against a panel of 528,509 “observed” discovery markers (DMs). DM/CV pairs with LD  $r^2 > 0.9$  were then tested in an independent sample. Simulation results of the proportional decrease between discovery and replication datasets in LD ( $y$ -axis) of  $\hat{r}^2, \hat{r}^4, \hat{r}^6, \hat{r}^8$  ( $x$ -axis) are shown, where  $\hat{r}_D^x$  and  $\hat{r}_R^x$  are the sample LD measurements in the discovery and replication datasets, respectively. The average proportional decrease in the replication  $\hat{r}_R^x$  was 2.8%, 5.3%, 7.4% and 9.2% for  $x = 2, 4, 6$  and 8, respectively.






Figure S10: **Genotype-phenotype maps for 14 interactions influencing the expression of MBNL1** Each bar represents the mean phenotypic value for individuals in that genotype class. The rs13069559 SNP typically has a *cis*-additive decreasing effect on the expression of MBNL1, but in many of these interactions the *cis* effect is masked when the *trans* SNP is homozygous for the masking allele.




Figure S11: **Genotype-phenotype maps for 19 interactions influencing the expression of TMEM149** Each bar represents the mean phenotypic value for individuals in that genotype class. The rs13069559 SNP typically has a *cis*-additive decreasing effect on the expression of TMEM149, but in many of these interactions the *cis* effect is masked when the *trans* SNP is homozygous for the masking allele.




Figure S12: **Genotype-phenotype maps for 8 interactions influencing the expression of NAPRT1** Each bar represents the mean phenotypic value for individuals in that genotype class.




Figure S13: **Genotype-phenotype maps for 16 interactions influencing the expression of TRAPPC5** Each bar represents the mean phenotypic value for individuals in that genotype class.





Figure S14: **Genotype-phenotype maps for 15 interactions influencing the expression of CAST** Each bar represents the mean phenotypic value for individuals in that genotype class.



**Figure S15: Number of overlaps between chromosome interactions and epistatic interactions** Interacting chromosome regions may be a possible mechanism underlying epistatic interactions. The number of epistatic interactions within 20kb, 500kb, 2Mb and 10Mb of known chromosome interacting regions are shown by red vertical lines. The histograms represent the null distribution based on random sampling of 1,000 datasets for each window size.





Figure S16: **Comparison of allele frequencies for 781 SNPs involved in genetic interactions across independent populations** Outliers were removed from the analysis as part of the filtering stage during replication.



**Figure S17: Comparison of variance explained by additive, dominant and epistatic effects from different cohorts** How does the estimated variance decomposition change in different cohorts? The proportion of the phenotypic variance that is additive (A), dominant (D), or epistatic (I) for each putative interaction is shown on the  $y$ -axis (Note: different scales for each row). BSGS has 501 interactions whereas Fehrmann and EGCUT have 434 ( $x$ -axis). The variance estimates in each plot are ordered from lowest additive to highest. This is done independently for each cohort to depict the distribution of estimated effects.



395 **Supplementary Tables**



Table S1 – continued from previous page

Expression trait			SNP 1			SNP 2			Interaction statistic / -log <sub>10</sub> p-values			Distance / Mb		
Gene ID <sup>a</sup>	Probe ID <sup>b</sup>	Chr.	rs ID	Chr.	Pos /Mb <sup>c</sup>	Association <sup>d</sup>	rs ID	Chr.	Pos /Mb <sup>c</sup>	Association <sup>d</sup>	BSGS <sup>e</sup>		Fehrmann <sup>f</sup>	EGCUT <sup>g</sup>
CBORF59	ILMN_1633205	8	rs8051751	16	7188323		rs2896452	8	86102223	CBORF59	5.79	1.39	0.18	0.87
CBORF72	ILMN_1741881	9	rs10122902	9	27556780	C9ORF72	rs2526698	1	242029101		6.36	0.96	0.01	0.37
CAC1	ILMN_1731064	1	rs12765847	10	4353908		rs3738725	1	227174210	CAC1	6.36	0.94	0.00	0.34
CARD9	ILMN_1712532	9	rs4260763	9	139289825	INPP5E	rs684040	1	82128660		5.81			
CAST	ILMN_1717234	5	rs4573661	11	6026661		rs4077515	9	139266496	INPP5E	6.61	0.09	0.86	0.42
CAST	ILMN_1717234	5	rs112463169	19	17321669		rs7733671	5	96000269	CAST	7.07	0.23	0.96	0.62
CAST	ILMN_1717234	5	rs12463169	19	17321669		rs7733671	5	96000269	CAST	5.73	0.02	2.85	1.75
CAST	ILMN_1717234	5	rs12599264	16	81840122		rs7733671	5	96000269	CAST	7.00			
CAST	ILMN_1717234	5	rs12719343	5	125369113		rs7733671	5	96000269	CAST	7.08	0.36	1.57	29.369
CAST	ILMN_1717234	5	rs1410575	9	78255630		rs7733671	5	96000269	CAST	6.55	0.13	1.34	0.78
CAST	ILMN_1717234	5	rs166444	8	78392770		rs7733671	5	96000269	CAST	7.01	0.27	0.52	0.37
CAST	ILMN_1717234	5	rs17648036	15	27311111		rs7733671	5	96000269	CAST	7.81	0.97	0.03	0.41
CAST	ILMN_1717234	5	rs17818702	11	86107920		rs7733671	5	96000269	CAST	6.62	1.15	0.59	1.09
CAST	ILMN_1717234	5	rs227402	21	70496867		rs7733671	5	96000269	CAST	6.12	0.11	0.01	0.01
CAST	ILMN_1717234	5	rs2822124	21	15166804		rs7733671	5	96000269	CAST	6.87			
CAST	ILMN_1717234	5	rs3757155	6	136458593		rs7733671	5	96000269	CAST	7.24	0.07	0.33	0.12
CAST	ILMN_1717234	5	rs4503014	7	31149140		rs7733671	5	96000269	CAST	5.88	0.92	1.56	1.72
CAST	ILMN_1717234	5	rs7474890	10	59590078		rs7733671	5	96000269	CAST	6.74	0.49	0.12	0.23
CAST	ILMN_1717234	5	rs7733671	5	96000269	CAST	rs10802643	1	238120177		7.42	0.75	0.78	0.93
CAST	ILMN_1717234	5	rs7733671	5	96000269	CAST	rs12650909	2	170192890		7.42	0.23	0.87	0.54
CAST	ILMN_1717234	5	rs7733671	5	96000269	CAST	rs2203733	2	224093101		6.07	0.22	0.78	0.50
CAST	ILMN_1717234	5	rs7733671	5	96000269	CAST	rs2641772	3	195531841		6.93	0.19	0.26	0.15
CAT	ILMN_1651705	11	rs872311	18	66175386		rs541207	11	34447586	CAT	6.41	0.26	0.30	0.22
CCDC88B	ILMN_1722208	11	rs23532303	19	17099980		rs541207	11	64125142	CCDC88B	5.68	0.33	0.37	0.31
CCDC88B	ILMN_1772208	11	rs694739	11	64097233	CCDC88B	rs12771349	10	96989193		5.62	0.23	0.18	0.14
CD36	ILMN_1784663	7	rs3211834	11	76033374		rs1254900	2	85816334	CD36	6.93	0.15	0.01	0.02
CD55	ILMN_1800540	1	rs750801	11	80283117		rs6701068	1	207502534	CD55	5.09	0.03	0.03	0.02
CD93	ILMN_1704730	20	rs1884655	20	23074375	CD93	rs10255470	7	157182040	VAMP8	6.06	1.74	0.24	1.20
CD93	ILMN_1704730	20	rs1884655	20	23074375	CD93	rs4696726	4	7992632		5.71	0.13	0.80	0.42
CD93	ILMN_1704730	20	rs1884655	20	23074375	CD93	rs7622580	3	196721395		5.56	0.04	0.27	0.08
CD93	ILMN_1704730	20	rs1884655	20	23074375	CD93	rs838875	12	125145394		6.31	0.24	1.67	1.16
CD93	ILMN_1704730	20	rs1884655	20	23074375	CD93	rs9576388	13	38434472	CD93	7.88	0.71	0.22	0.45
CD93	ILMN_1704730	20	rs2868504	20	37771578		rs1884655	20	23074375		5.71			
CD93	ILMN_1704730	20	rs4813479	20	23076914	CD93	rs10925747	1	238899903		7.43			
CD93	ILMN_1704730	20	rs4813479	20	23076914	CD93	rs2873420	8	136500554		7.02			
CD93	ILMN_1704730	20	rs4813479	20	23076914	CD93	rs4295531	18	74439542		6.13			
CD93	ILMN_1704730	20	rs4813479	20	23076914	CD93	rs7489981	17	77264482		6.08			
CD93	ILMN_2309796	13	rs861544	14	104162263		rs7324744	13	115008038	CD93	5.46	0.21	0.14	0.11
CDK5R1	ILMN_1730928	17	rs9905940	17	46614102	HOXB2	rs11655031	17	30833162	CDK5R1	5.47	0.95	0.07	0.45
CEACAM21	ILMN_1745949	19	rs200690	20	46614102		rs4803481	19	42066556	CEACAM21	6.15	0.90	0.12	0.48
CEACAM21	ILMN_1745949	19	rs4803481	19	42066556	CEACAM21	rs2421050	5	158943044	CEACAM21	6.67	2.16	0.16	1.44
CEP192	ILMN_1703754	18	rs6505780	18	13069792	CEP192	rs13132719	4	180265266		5.75	0.15	0.24	0.12
CEP63	ILMN_1787808	3	rs3825569	14	101350298		rs13079012	3	134247706	ANAPC13	6.36	0.23	0.10	0.09
CES1	ILMN_2359945	16	rs81992935	16	55861794	CES1	rs772788	2	235248562		5.65			
CHPT1	ILMN_2209240	12	rs591967	13	38838122		rs2695290	12	102087844	CHPT1	5.74	0.72	0.20	0.44
CHPT1	ILMN_2209240	12	rs6539014	12	102277782		rs867578	11	81937002		4.75	0.92	0.02	0.36
CLEC12A	ILMN_1663142	12	rs429790	16	84471642		rs7313235	12	10132283	CLEC12A	5.55	0.07	1.28	0.67
CLEC12A	ILMN_2403228	12	rs7305054	11	91056646		rs3903088	10	134236688		7.54	0.95	0.36	0.73
CLEC12A	ILMN_1674609	5	rs17129799	11	96929337		rs6863172	5	173595960	CLTB	5.55		0.27	
CNN2	ILMN_1770290	19	rs3752237	19	1047161	ABCA7	rs169130	16	63121080		7.56	0.07	0.02	0.02
CNN2	ILMN_1770290	19	rs3752237	19	1047161	ABCA7	rs7336017	13	67713633		6.33	1.92	0.28	1.39
CP5F1	ILMN_1654545	8	rs4336345	8	145569535		rs1455268	4	61738094		6.34	0.10	0.01	0.01
CPVL	ILMN_1682928	7	rs12596791	16	26115562		rs2455884	7	29188475	CPVL	5.74	0.06	0.57	0.23

Continued on next page

Table S1 – continued from previous page

Gene ID <sup>a</sup>	Expression trait <sup>b</sup>	SNP 1			SNP 2			Interaction statistic / -log <sub>10</sub> p-values			Distance / Mb <sup>h</sup>		
		rs ID	Chr.	Pos/Mb <sup>c</sup>	Association <sup>d</sup>	rs ID	Chr.	Pos/Mb <sup>c</sup>	Association <sup>d</sup>	BSGS <sup>e</sup>		Fehrmann <sup>f</sup>	EGCUT <sup>g</sup>
CPVL	ILMN-1682928	rs2835998	21	39202070		rs245884	7	29185475	CPVL	5.55	0.19	0.03	0.04
CRPT	ILMN-1813256	rs2131290	4	188539908		rs1531133	7	46843631	CRPT	5.47	0.28	0.10	0.12
CRUS1	ILMN-1737685	rs6139887	20	5986234	CRUS1	rs1473927	5	62406408		6.18	0.10	0.36	0.15
CS1B	ILMN-1761797	rs69979356	21	43230974		rs3761385	21	45196355		11.99	22.67	16.72	42.27
CTNNA1	ILMN-1804854	rs924943	18	69000505		rs176382	5	138226707	CTNNA1	5.74	0.02	0.41	0.11
CTSC	ILMN-1696347	rs2457684	11	88139983	CTSC	rs7079264	10	10679892		5.67	0.92	0.74	0.03
CTSC	ILMN-1696347	rs75732236	22	26250645		rs1728352	11	88077457	CTSC	5.84	0.49	0.73	0.03
CTSC	ILMN-2242463	rs7930237	11	88117962		rs12784396	10	102027407		7.16	18.76	15.06	33.53
CWF19L1	ILMN-1651886	rs7108734	11	11450027		rs12784396	10	102027407	CWF19L1	5.42	0.21	0.01	0.03
CYBRD1	ILMN-1712305	rs2592948	4	129994690		rs888427	2	172366120	CYBRD1	5.89	0.23	0.53	0.34
CYBRD1	ILMN-1712305	rs7852475	9	140698856		rs888427	2	172366120	CYBRD1	5.68	0.20	0.02	0.04
CYBRD1	ILMN-2087692	rs11257679	10	12318284		rs888427	2	172366120	CYBRD1	5.81	0.39	1.87	1.47
CYBRD1	ILMN-2087692	rs6137908	20	23344590		rs888427	2	172366120	CYBRD1	5.53	0.05	0.83	0.36
CYP27A1	ILMN-1704985	rs888427	2	172366120	CYBRD1	rs7591849	2	160112881	CYP27A1	5.85	0.87	0.10	0.44
CYP27A1	ILMN-1704985	rs6021982	20	36571928		rs933994	2	219650616	CYP27A1	5.42	0.29	0.86	0.60
DAB2	ILMN-2128428	rs7778910	17	110451383		rs835223	5	39381357	DAB2	5.44	0.48	0.41	0.44
DDT	ILMN-1811648	rs9900173	17	43111688	DDT	rs1343244	9	82076988		9.12	0.00	0.58	0.14
DDT	ILMN-1690982	rs9760102	22	24248761		rs278341	3	187475208		5.62	0.64	0.25	0.42
DDX58	ILMN-1797001	rs4837097	11	125962645		rs7042042	7	32451144		5.47	0.61	0.29	0.44
DEM1	ILMN-1783996	rs10120023	9	137810259	COQ10A	rs10120023	9	137810259	COQ10A	5.31	0.08	0.41	0.16
DEM1	ILMN-1733998	rs12363827	12	106703727		rs7566044	2	169960422	DHRS9	6.39	0.77	0.02	0.29
DHRS9	ILMN-1733998	rs15119566	12	89468283		rs7566044	2	169960422	DHRS9	6.00	0.06	1.17	0.58
DHRS9	ILMN-2384181	rs2528529	12	147132505		rs2161037	2	169896044	DHRS9	6.48	0.37	0.34	0.32
DHRS9	ILMN-2384181	rs2831914	21	29959453		rs2161037	2	169893419	DHRS9	5.51	0.88	0.04	0.37
DHRS9	ILMN-2384181	rs7661304	4	187776431		rs11669322	12	50610976	LASS5	7.64	0.05	0.11	0.03
DP2B	ILMN-1755589	rs11080134	17	29161503	LASS5	rs2872008	7	153134888	LASS5	4.87	0.30	0.58	0.19
DP2B	ILMN-1755589	rs1166935	12	50636364		rs7134595	12	50730458		5.31	0.38	0.22	0.19
DP2B	ILMN-1755589	rs3383855	19	41711815	LASS5	rs1808634	8	61971140	LASS5	4.40	0.37	0.09	0.02
DP2B	ILMN-1755589	rs7314505	12	50730458	LASS5	rs4529358	10	115214154	LASS5	5.03	0.48	0.00	0.11
DP2B	ILMN-1755589	rs7312252	12	50744171	LASS5	rs12427378	12	51074199	DNABJB6	5.92	0.23	1.45	0.97
DP2B	ILMN-1755589	rs171957	12	117994348		rs3775539	7	157163614	DNABJB6	5.79	0.23	1.45	0.97
DNABJB6	ILMN-1793770	rs2288842	7	157216093		rs1566972	3	16320360	DPH3	6.17	1.58	0.27	1.12
DPH3	ILMN-2140610	rs12252308	15	93409054	ECGF1	rs4891884	18	64004670	DPH3	4.81	0.15	1.18	0.70
ECGF1	ILMN-2109708	rs1432322	22	50971266	ECGF1	rs1560954	18	53402552	ECGDC2	6.19	0.22	0.35	0.22
ECGF1	ILMN-1671568	rs4324091	22	241911027		rs11206043	1	53402552	ECGDC2	5.58	0.64	0.16	0.35
ECGDC2	ILMN-1671568	rs5092637	22	17675900		rs1048166	15	42192040	ECGDC2	6.98	0.90	0.47	0.79
ECGDC2	ILMN-1720083	rs10403312	19	53244938		rs1754556	14	75503430	EIF2B2	5.56	0.23	0.11	0.10
EIF2B2	ILMN-1719380	rs6567288	18	60218334	EIF5A	rs1269096	14	96603119	EIF2B2	5.44	0.56	0.08	0.24
EIF5A	ILMN-1794522	rs7216490	17	7221707	EIF5A	rs1269096	14	96603119	EIF5A	5.44	0.23	0.35	0.22
EIF5A	ILMN-1794522	rs7216490	17	7221707	EIF5A	rs1553474	2	49359676	EIF5A	5.55	0.28	0.59	0.41
EIF5A	ILMN-1794522	rs7216490	17	7221707	EIF5A	rs1269096	14	96603119	EIF5A	5.55	0.28	0.59	0.41
EIF5A	ILMN-1794522	rs7216490	17	7221707	EIF5A	rs4471434	11	126387391	EMR2	6.36	0.08	0.05	0.02
EMR2	ILMN-2353633	rs2827076	17	23196249		rs9305048	19	14879034	EMR2	5.52	0.05	1.12	0.53
EMR2	ILMN-2353633	rs6132112	20	18761714		rs9305048	19	14879034	EMR2	5.51	0.36	0.04	0.11
EMR2	ILMN-2353633	rs9405048	19	14879034	EMR2	rs3007765	13	102480759	EMR2	6.03	0.45	0.40	0.41
EPHX2	ILMN-1709237	rs1109764	11	12790396		rs13269963	8	27400604	EPHX2	5.70	0.20	0.58	0.35
EPHX2	ILMN-1731001	rs10894861	11	13461176		rs12115088	8	578742	EPHX2	5.43	0.25	1.20	0.81
EPHX2	ILMN-1731001	rs5766218	22	45337329		rs12115088	8	578742	EPHX2	6.11	0.20	0.11	0.09
EPHX2	ILMN-1731001	rs726145	18	31187910	ERICH1	rs12115088	8	578742	ERICH1	5.63	0.29	0.04	0.08
ERICH1	ILMN-2104696	rs4735895	8	600729		rs1517297	4	182786760	ERICH1	5.63	0.67	1.03	1.06
ERICH1	ILMN-1789419	rs187076	10	55228462		rs12188164	5	4928236	EXOC3	6.83	0.74	0.19	0.44
EXOC3	ILMN-2246661	rs1560104	16	12708208		rs344363	16	1972548	EXOC3	5.61	0.38	1.38	0.23
FAHD1	ILMN-1668063	rs12580388	12	129591144		rs10120023	9	137810259	FAHD1	6.33	0.27	0.30	0.30

Continued on next page

Gene ID <sup>a</sup>			Expression trait			SNP 1			SNP 2			Association <sup>d</sup>			Interaction statistic <sup>c</sup> - log <sub>10</sub> p-values			Distance / Mb		
rs ID	Chr.	Probe ID <sup>b</sup>	rs ID	Chr.	Pos / Mb <sup>c</sup>	Association <sup>d</sup>	rs ID	Chr.	Pos / Mb <sup>c</sup>	Association <sup>d</sup>	BSGS <sup>e</sup>	Fehrmann <sup>f</sup>	EGCUT <sup>g</sup>	Metag <sup>h</sup>						
PEZ2	2	ILMN_1739586	rs2356400	19	43221776		rs13406184	2	36791226	PEZ2	5.78	0.14	0.33	0.16						
PEZ2	2	ILMN_1739586	rs969010	4	15963132		rs11691600	2	36791226	PEZ2	6.59	0.14	0.28	0.14						
FCGD2	6	ILMN_2115005	rs4803848	19	46205050		rs831486	6	37901267	FCGD2	5.49	1.20	0.25	0.11						
FCGD2	6	ILMN_2115005	rs902634	10	133943951		rs831489	6	36999682	FCGD2	5.49	1.20	0.25	0.11						
FLJ20489	12	ILMN_1778144	rs17615703	12	117036766		rs3782908	12	48169526	FLJ20489	5.81	0.06	0.70	0.29			68.867			
FLJ20489	12	ILMN_1778144	rs3782908	12	48169526	FLJ20489	rs897511	4	167695661		5.53	0.03	0.11	0.02						
FLJ20489	12	ILMN_1778144	rs4792199	17	7992118		rs3782908	12	48169526	FLJ20489	5.74	0.19	0.02	0.04						
FLJ20489	12	ILMN_1778144	rs4984440	15	97033129		rs3782908	12	48169526	FLJ20489	6.49	0.31	0.47	0.36						
FLJ20489	12	ILMN_1778144	rs7204135	16	50626195		rs3782908	12	48169526	FLJ20489	6.90	0.38	0.17	0.21						
FLJ20718	18	ILMN_1763663	rs9325634	21	43818790		rs278197	16	50106594	FLJ20718	6.04	0.14	0.95	0.53						
FLJ43093	6	ILMN_2123450	rs1112712	14	107276627		rs6906101	6	36667610	FLJ43093	5.48	0.39	0.06	0.13						
FLJ43093	6	ILMN_2123450	rs6906101	6	36667610		rs13214069	6	32705248		5.44	0.00	0.64	0.18			3.962			
FN3KRP1	17	ILMN_1652333	rs898095	17	80380638		rs9892064	17	80827903		16.16	28.24	29.39	59.95			0.063			
FXFD5	19	ILMN_2309848	rs4971478	2	1346063		rs12744386	1	24168019	FUCA1	6.41	0.01	0.30	0.06						
FXFD5	19	ILMN_2309848	rs1633921	20	35659200		rs788178	13	98328559		3.70	0.09	0.41	0.17						
FXFD5	19	ILMN_2309848	rs1739183	20	5609148		rs2285515	19	35660450	FXFD5	6.58	0.03	0.48	0.15						
FXFD5	19	ILMN_2309848	rs2285515	19	35660450	FXFD5	rs11739594	5	141709563		5.70	0.07	0.17	0.05						
FXFD5	19	ILMN_2309848	rs2285515	19	35660450	FXFD5	rs13067700	3	95331048		6.00	0.09	0.09	0.51						
FXFD5	19	ILMN_2309848	rs2285515	19	35660450	FXFD5	rs17036504	2	47567329		6.10	0.28	0.08	0.37						
G3BP2	4	ILMN_2381768	rs10230232	7	29390239		rs1553985	4	76554604		5.19	0.08	0.37	0.14						
GAA	17	ILMN_2410783	rs11150847	17	78151330		rs12602462	17	13216016		13.91	19.98	12.99	32.60			0.007			
GAA	17	ILMN_2410783	rs8068856	17	78100731		rs10902506	12	782678089		5.65	0.11	0.39	0.17						
GAP	5	ILMN_1675191	rs10070522	5	57786117	GAA	rs7605821	2	235650228		5.85	0.01	0.78	0.28						
GAP	5	ILMN_1675191	rs7082031	10	128038717	GAPT	rs10070522	5	57786											

Continued on next page

Table S1 – continued from previous page

Gene ID <sup>a</sup>	Expression trait	Chr.	rs ID	Chr.	SNP 1	Pos/Mb <sup>c</sup>	Association <sup>d</sup>	rs ID	Chr.	SNP 2	Pos/Mb <sup>c</sup>	Association <sup>d</sup>	BSGS <sup>e</sup>	Interaction statistic <sup>f</sup>	-log <sub>10</sub> p-values	Meta <sup>g</sup>	Distance / Mb <sup>h</sup>
HBG2	ILMN.2084825	11	rs12975066	19	37233501		HBG2	rs2855039	11	5271671		HBG2	5.77	0.08	0.13	0.05	
HBG2	ILMN.2084825	11	rs2855039	11	5271671		HBG2	rs12042181	1	213085494		HBG2	6.84	0.06	0.34	0.21	
HBG2	ILMN.2084825	11	rs2855039	11	5271671		HBG2	rs12053379	4	141533832		HBG2	5.98	0.00	0.46	0.10	
HBG7	ILMN.1860286	12	rs2109029	16	6036851		HBG7	rs47060636	12	48173352		HBG7	5.73	0.15	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622		HEBP1	5.98	0.00	0.59	0.32	
HEBP1	ILMN.1860257	12	rs3782507	12	13145013		HEBP1	rs176866535	17	1332200622							

3.30 Continued on next page

Table S1 – continued from previous page

[illegible]

Continued on next page

Expression trait			SNP 1			SNP 2			Interaction statistic / $-\log_{10} p$ -values			Distance / Mb	
Gene ID <sup>a</sup>	Chr.	rs ID	Chr.	Pos /Mb/c	Association <sup>d</sup>	rs ID	Chr.	Pos /Mb/c	Association <sup>d</sup>	BSGS <sup>e</sup>	Fehrmann <sup>f</sup>	EGCUT <sup>g</sup>	Meta <sup>g</sup>
ILMN_3237385	10	rs6025645	20	56157341		rs7923609	10	65133822	NRRF2	5.45			
ILMN_3237385	10	rs617815	20	19819016		rs7923609	10	65133822	NRRF2	6.11			
ILMN_1800897	8	rs6517815	21	19819016		rs7923609	10	65133822	NRRF2	6.13	0.47	0.05	0.17
ILMN_1800897	8	rs4852124	2	240680022		rs6588415	1	52334047	NRRF2	5.44	0.03	0.46	0.15
ILMN_1658247	12	rs5017815	2	24534382		rs1005901	8	21963478	NUDT18	8.19	1.27	1.55	2.03
ILMN_1658247	12	rs11613438	12	113480510		rs1047944	6	163997467	NUDT18	4.13	4.12	0.81	3.86
ILMN_1658247	12	rs13311	12	113480510		rs2072133	12	113402600		4.38	0.87	0.46	0.76
ILMN_1675640	12	rs1892233	19	49160255		rs3741981	12		OAS1	5.64	0.42	0.06	0.14
ILMN_2381899	16	rs7912613	16	74286646		rs17512962	10	13169066	OAS1	5.00	0.36	0.00	0.47
ILMN_2307032	11	rs2829679	17	26662143		rs988639	11	3149249	OSBPL5	5.42	0.16	0.87	0.40
ILMN_1742456	9	rs17750195	17	70624189	OSTF1	rs2273770	9	77755469	OSTF1	5.42	0.16	0.87	0.40
ILMN_1742456	9	rs2273770	9	77755469	OSTF1	rs7718088	5	179590952		5.42	1.20	0.08	0.62
ILMN_1734542	1	rs10802822	1	240132968		rs1718088	5	111992823	OVG1	5.43	0.13	1.48	0.88
ILMN_1734542	1	rs347331	3	140148107	PAM	rs1264894	1	119697919	OVG1	6.04	0.25	1.21	0.82
ILMN_2313901	5	rs28092	5	102149795	PCYOX1L	rs784600	1	40139553	HPCAL4	5.59	0.66	0.44	0.59
ILMN_1815951	5	rs2438490	5	182726162		rs2731939	3	2395989		6.20	0.19	0.26	0.16
ILMN_1660232	12	rs10444467	12	128052636		rs4329748	12	7364442	PEX5	5.85	0.09	0.71	0.32
ILMN_1660232	12	rs4329748	12	128052636		rs4329748	12	7364442	PEX5	5.74	0.34	0.09	0.13
ILMN_1660232	12	rs7495797	15	27246462		rs7328733	13	33126737	PPAAP5	5.64	0.87	0.36	0.67
ILMN_1797893	13	rs7328733	13	49151303	PGLYRP1	rs1263806	14	21982957	PPAAP5	5.51	0.03	0.65	0.24
ILMN_1704870	19	rs2982353	19	46529456		rs10736812	11	7670806	PHCA	6.51	0.36	0.90	0.70
ILMN_1812552	22	rs4141404	22	31675185	PIK3P1	rs10736812	11	7670806	PHCA	5.60	0.20	0.81	0.33
ILMN_1719934	22	rs470072	22	32263131	PISD	rs2065841	14	30398876		5.23	0.02	0.87	0.48
ILMN_1799394	22	rs6518752	22	31999127	PISD	rs545627	1	18236681		7.11	0.00	1.19	0.48
ILMN_1799394	22	rs715572	22	33234931		rs6518754	22	32097775	PISD	4.12	0.05	0.42	0.15
ILMN_174604	9	rs6869411	16	158781604		rs928046	9	149482481	PNDL7	6.35	0.16	0.04	0.04
ILMN_1662587	9	rs11639998	16	4527109		rs928046	9	149482481	PNDL7	5.15	0.31	0.78	0.56
ILMN_1662587	9	rs911019	20	49686325		rs1156801	11	7559930	PPF1P2	4.44	0.29	0.33	0.26
ILMN_1662617	1												

Continued on next page



Table S1 – continued from previous page

Gene ID <sup>a</sup>			Expression trait			SNP 1			SNP 2			Interaction statistic <sup>f</sup>			BGS <sup>g</sup>			-log <sub>10</sub> p-values			Distance / Mb <sup>b</sup>		
Gene	ID <sup>a</sup>	Chr.	rs ID	Chr.	Pos/Mb <sup>c</sup>	Association <sup>d</sup>	rs ID	Chr.	Pos/Mb <sup>c</sup>	Association <sup>d</sup>	rs ID	Chr.	Pos/Mb <sup>c</sup>	F <sub>DR</sub>	F <sub>DR</sub> max	Meta <sup>g</sup>	EGCUT <sup>e</sup>	Meta <sup>g</sup>	EGCUT <sup>e</sup>	Meta <sup>g</sup>	EGCUT <sup>e</sup>	Distance / Mb <sup>b</sup>	
RENE	ILMN_1802830	1	rs4982958	14	24987865		rs301819	1	8501786	RENE	rs301819	1	8501786	5.66	0.61	1.23	1.17						
RENE	ILMN_1802830	1	rs7697290	4	135248366		rs301819	1	8501786	RENE	rs301819	1	8501786	5.74	0.14	0.10	0.06						
RENE	ILMN_1802830	1	rs11085629	19	13174312		rs301819	1	8501786	RENE	rs301819	1	8501786	5.72	0.21	0.33	0.21						
RENE	ILMN_2347795	14	rs38520111	3	12844086	RNASE6	rs301819	1	8501786	RENE	rs301819	1	8501786	5.71	0.08	0.60	0.26						
RENE	ILMN_2347795	14	rs10218598	14	21182850		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14	rs38520111	3	12844086		rs75234365	13	107601327	RNASE6	rs75234365	13	107601327	5.48	0.42	0.21	0.26						
RENE	ILMN_2347795	14</																					

Continued on next page

	SNP 2	Interaction statistic / —	og <sub>10</sub> p-values
--	-------	------------------------------	---------------------------

Continued on next page

Table S1 – continued from previous page

Expression trait			SNP 1			SNP 2			Interaction statistic <sup>f</sup> / -log <sub>10</sub> p-values			Distance / Mb <sup>h</sup>		
Gene ID <sup>a</sup>	Probe ID <sup>b</sup>	Chr.	rs ID	Chr.	Pos / Mb <sup>c</sup>	Association <sup>d</sup>	rs ID	Chr.	SNP-2	Association <sup>d</sup>	BSGS <sup>e</sup>	Fehrmann <sup>f</sup>	EGCUT <sup>g</sup>	Meta <sup>g</sup>
UBASH3A	LMN-2338348	21	rs1893592	21	43855067	UBASH3A	rs7201194	16	83600397		5.91	0.59	0.42	0.52
UBASH3A	LMN-2338348	21	rs1893592	21	43855067	UBASH3A	rs7201194	16	83600397		6.01	0.48	1.29	1.10
USP36	LMN-1697227	17	rs2279308	17	76794981	USP36	rs7225546	17	75151717		5.71	0.03	0.14	0.03
VASP	LMN-1743646	19	rs1264226	19	40663167		rs2276470	19	45974668		5.09	0.94	5.14	4.95
VNN2	LMN-1678939	6	rs10435352	7	103252718		rs1883613	6	133077063	VNN2	5.64	0.84	0.15	0.46
VNN2	LMN-1678939	6	rs10435352	7	103252718		rs1883613	6	133077063	VNN2	5.64	0.84	0.15	0.46
VNN2	LMN-1678939	6	rs134447	20	49927332		rs1883617	6	133072650	VNN2	5.44	0.39	0.69	0.57
VNN2	LMN-1678939	6	rs134447	20	49927332		rs1883617	6	133072650	VNN2	5.44	0.39	0.69	0.57
VNN3	LMN-1678939	6	rs216495	11	16834510		rs1883617	6	133072650	VNN2	5.77	0.33	0.19	0.19
VNN3	LMN-1678939	6	rs10278073	7	151662184		rs2267952	6	133067782	VNN3	6.44	0.16	0.74	0.41
VNN3	LMN-1804935	6	rs1443946	8	73006453		rs2267952	6	133067782	VNN3	5.74	0.23	0.48	0.31
VNN3	LMN-1804935	6	rs348462	9	75547169		rs2267952	6	133067782	VNN3	6.44	0.31	0.17	0.17
VNN3	LMN-1804935	6	rs7157055	14	83262064		rs2267952	6	133067782	VNN3	5.82	0.03	0.19	0.04
VNN3	LMN-2387680	6	rs2823165	21	5694253		rs2267952	6	133067782	VNN3	6.12	0.73	1.15	1.21
VNN3	LMN-2387680	6	rs9596457	13	51692548		rs2267952	6	133067782	VNN3	4.83	0.46	0.05	0.16
VSTM1	LMN-1763455	19	rs9596457	19	54553697		VSTM1	18	71024750		5.60	0.53	0.54	0.57
VSTM1	LMN-1763455	19	rs10500316	19	54553697	VSTM1	rs7895870	10	123098249		5.71	0.48	0.17	0.26
VSTM1	LMN-1763455	19	rs10500316	19	54553697	VSTM1	rs7895870	10	123098249		5.71	0.48	0.17	0.26
VSTM1	LMN-1763455	19	rs9628570	22	30261219		rs10500316	19	54553697	VSTM1	5.88	0.81	1.38	1.47
WDR48	LMN-1762103	3	rs1388935	3	188927822		rs6778963	3	39091812	WDR48	5.88	0.19	0.13	0.09
WDR48	LMN-1762103	3	rs1887778	9	134635088		rs883349	3	39067925	WDR48	6.34	0.57	1.35	1.22
WDR48	LMN-1762103	3	rs9554833	13	102624790		rs7619193	3	39044116	WDR48	5.85	0.18	0.61	0.35
WDR6	LMN-1669484	3	rs12362253	11	123371708		rs11715581	3	49194331	WDR6	4.86	1.64	1.43	2.25
XAF1	LMN-2330573	17	rs1535031	17	6673170	XAF1	rs12591171	15	93179799		5.48	2.38	0.17	1.63
ZFP90	LMN-1684628	16	rs960446	21	37040648		rs18128968	16	68573945	ZFP90	5.79	0.09	0.36	0.15
ZNF500	LMN-1700238	16	rs4282723	22	48283177		rs2290560	16	4799041	ZNF500	5.29	0.67	0.27	0.46
ZYX	LMN-1701875	7	rs6056281	20	8935312		rs2242601	7	143093824	ZYX	6.04	0.26	0.01	0.05

<sup>a</sup> Phenotypes are expression levels of RefSeq Genes<sup>b</sup> Illumina probe ID used to measure gene expression<sup>c</sup> Physical SNP position in base pairs (HG19)<sup>d</sup> RefSeq Gene ID of gene expression level that is influenced by the SNP (BSGS discovery dataset, significance threshold = 1.29 × 10<sup>-11</sup>)<sup>e</sup> Interaction - log<sub>10</sub> p-value from discovery dataset<sup>f</sup> Interaction - log<sub>10</sub> p-value from replication dataset<sup>g</sup> Interaction - log<sub>10</sub> p-value from meta analysis of replication datasets only<sup>h</sup> Distance in Mb between interacting SNPs for *cis-cis* acting SNP pairs<sup>i</sup> p-values are absent if the interaction did not pass the QC filtering in the replication dataset<sup>j</sup> Meta analysis p-values are absent if the interaction did not pass the QC filtering in either replication dataset

Table S2: **Estimation of additive and non-additive variance components from pedigree information** Taken from previous analysis in Powell et al 2013<sup>22</sup>

Gene	Probe	Additive		Non-additive	
		Variance	s.e.	Variance	s.e.
NAPRT1	ILMN_1710752	0.37	0.03	0.14	0.05
TMEM149	ILMN_1786426	0.41	0.04	0.09	0.04
MBNL1	ILMN_2313158	0.18	0.03	0.11	0.04
TRAPPC5	ILMN_2372639	0.32	0.04	0.13	0.05
CAST	ILMN_1717234	0.31	0.03	0.10	0.04

Table S3: **Concordance of sign of epistatic variance components between discovery and replication datasets**

Test	Interactions <sup>a</sup>	Dataset	$n^b$	Expected <sup>c</sup>	Observed <sup>d</sup>	$p$ -value
1 <sup>e</sup>	All	EGCUT	434	217.00	306	$6.69 \times 10^{-18}$
		Fehrmann	434	217.00	278	$5.04 \times 10^{-9}$
		Both	434	108.50	221	$5.56 \times 10^{-31}$
	Significant	EGCUT	30	15.00	25	$3.25 \times 10^{-4}$
		Fehrmann	30	15.00	24	$1.43 \times 10^{-3}$
		Both	30	7.50	22	$3.76 \times 10^{-8}$
2 <sup>f</sup>	All	EGCUT	434	54.25	92	$4.22 \times 10^{-7}$
		Fehrmann	434	54.25	79	$6.18 \times 10^{-4}$
		Both	434	6.78	30	$2.55 \times 10^{-11}$
	Significant	EGCUT	30	3.75	19	$9.46 \times 10^{-11}$
		Fehrmann	30	3.75	19	$9.46 \times 10^{-11}$
		Both	30	0.47	18	$2.23 \times 10^{-25}$
3 <sup>g</sup>	All	EGCUT	1133	566.50	775	$7.10 \times 10^{-36}$
		Fehrmann	1133	566.50	726	$1.90 \times 10^{-21}$
		Both	1133	283.25	562	$1.39 \times 10^{-70}$
	Significant	EGCUT	73	36.50	55	$1.69 \times 10^{-5}$
		Fehrmann	73	36.50	55	$1.69 \times 10^{-5}$
		Both	73	18.25	46	$7.86 \times 10^{-12}$

<sup>a</sup> “All” denotes 434 discovery interactions and “Significant” denotes 30 interactions with significant replication  $p$ -values

<sup>b</sup> Number of tests for concordance

<sup>c</sup> Expected number of concordant cases under the null hypothesis of no interactions

<sup>d</sup> Observed number of concordant cases

<sup>e</sup> The sign of the most significant epistatic variance component in discovery is the same as the corresponding variance component in the replication data.

<sup>f</sup> The largest epistatic variance component in the discovery is the same as in the replication with the same sign in both.

<sup>g</sup> The sign of all epistatic variance components in the discovery with  $p < 0.05$  are the same as the corresponding variance components in the replication data.

Table S4: **Concordance of sign of epistatic variance components between discovery and replication datasets using test 4**

Interactions <sup>a</sup>	Dataset	$n^b$	0 <sup>c</sup>	1 <sup>c</sup>	2 <sup>c</sup>	3 <sup>c</sup>	4 <sup>c</sup>	$p$
Expected <sup>d</sup>	-	-	0.06	0.25	0.38	0.25	0.06	-
All	EGCUT	434	0.06	0.22	0.41	0.23	0.08	0.194
All	Fehrman	434	0.07	0.22	0.39	0.24	0.08	0.385
All	Combined	868	0.07	0.22	0.40	0.23	0.08	0.0448
Significant	EGCUT	30	0.07	0.03	0.30	0.33	0.27	$4.72 \times 10^{-4}$
Significant	Fehrman	30	0.03	0.07	0.33	0.27	0.30	$6.69 \times 10^{-4}$
Significant	Combined	60	0.05	0.05	0.32	0.30	0.28	$5.49 \times 10^{-8}$

<sup>a</sup> “All” denotes 434 discovery interactions and “Significant” denotes 30 interactions with significant replication  $p$ -values.

<sup>b</sup> Number of tests for concordance.

<sup>c</sup> Proportion of tests that have 0, 1, 2, 3 or 4 concordant signs between discovery and replication.

<sup>d</sup> Expected proportion of concordant signs under the null hypothesis of no epistasis.

Table S5: Details on linkage disequilibrium and relative positions of all discovery *cis-cis* interactions

Chr	Gene	SNP 1	SNP 2	Position 1	Position 2	Distance / Mb	$R^2$	$D'$
19	TMEM149	rs807491	rs7254601	36268923	36147315	0.122	0.000	0.001
17	FN3KRP	rs898095	rs9892064	80890638	80827903	0.063	0.063	0.088
21	CSTB	rs9979356	rs3761385	45230974	45198355	0.033	0.041	0.066
3	MBNL1	rs16864367	rs13079208	152234166	152116652	0.118	0.041	0.117
10	ADK	rs2395095	rs10824092	76446305	75929517	0.517	0.013	0.020
11	CTSC	rs7930237	rs556895	88117962	88077479	0.040	0.012	0.045
17	GAA	rs11150847	rs12602462	78153130	78146016	0.007	0.000	0.001
8	NAPRT1	rs2123758	rs3889129	144663661	144613680	0.050	0.053	0.060
1	LAX1	rs1891432	rs10900520	203877662	203780591	0.097	0.065	0.106
18	MBP	rs8092433	rs4890876	74747424	74732087	0.015	0.035	0.053
11	SNORD14A	rs2634462	rs6486334	17339127	17015557	0.324	0.008	0.012
21	C21ORF57	rs9978658	rs11701361	48027084	47764477	0.263	0.032	0.065
16	RPL13	rs352935	rs2965817	89648580	89513234	0.135	0.054	0.060
19	ATP13A1	rs4284750	rs873870	19810050	19738554	0.071	0.008	0.015
2	NCL	rs7563453	rs4973397	232301670	232291471	0.010	0.027	0.029
5	HNRPH1	rs6894268	rs4700810	179032488	178991794	0.041	0.000	0.001
19	VASP	rs1264226	rs2276470	46063167	45974668	0.088	0.018	0.022
7	TRA2A	rs7776572	rs11770192	23528927	23498358	0.031	0.064	0.064
21	PRMT2	rs2839372	rs11701058	48063862	47776382	0.287	0.100	0.122
12	OAS1	rs13311	rs2072133	113448652	113409260	0.039	0.002	0.016
16	N4BP1	rs12444224	rs11649236	87580855	48632478	38.948	0.007	0.021
5	CAST	rs12719343	rs7733671	125369113	96000269	29.369	0.001	0.001
7	DNAJB6	rs2286842	rs3779589	157216093	157163614	0.052	0.005	0.006
1	OVGP1	rs10802822	rs1264898	240132968	111992823	128.140	0.008	0.030
20	CD93	rs2868504	rs1884655	37771578	23074375	14.697	0.000	0.002
11	PHCA	rs493642	rs10736812	123097386	76708086	46.389	0.002	0.008
21	MX1	rs459498	rs8130120	42795027	29363604	13.431	0.000	0.000
16	AKTIP	rs2896940	rs13332406	57721127	53489705	4.231	0.000	0.001
17	CDK5R1	rs9905940	rs11655031	46614102	30833162	15.781	0.000	0.000
2	CYBRD1	rs888427	rs7591849	172368120	160112881	12.255	0.000	0.000
8	HMBX1	rs587639	rs7837237	132725731	28876221	103.850	0.001	0.001
11	TRAPPC4	rs1793823	rs3916581	131018917	118887887	12.131	0.001	0.002
12	PEX5	rs10444467	rs4329748	128052636	7364442	120.688	0.000	0.000
12	FLJ20489	rs17615703	rs3782908	117036766	48169526	68.867	0.001	0.002
16	PRKCB1	rs2188355	rs10492793	23867776	12639800	11.228	0.000	0.000
14	MRPL52	rs1950857	rs3811188	26710271	23299135	3.411	0.002	0.004
17	C17ORF60	rs9907897	rs7405659	63502633	59874129	3.629	0.004	0.011
6	FLJ43093	rs6906101	rs13214069	36667610	32705248	3.962	0.000	0.000
19	TRAPPC5	rs17159840	rs17763599	7758194	2369415	5.389	0.000	0.000
22	PISD	rs715572	rs6518754	33234931	32097775	1.137	0.001	0.003
12	DIP2B	rs871257	rs12427378	117994348	51074199	66.920	0.001	0.001
12	GPR162	rs2272500	rs2707210	79685913	6902002	72.784	0.003	0.005
17	USP36	rs2279308	rs7225546	76794981	75151717	1.643	0.000	0.000